PE20142170A1 - Anticuerpos frente a los ligandos del receptor b1 de bradicinina - Google Patents

Anticuerpos frente a los ligandos del receptor b1 de bradicinina

Info

Publication number
PE20142170A1
PE20142170A1 PE2014001473A PE2014001473A PE20142170A1 PE 20142170 A1 PE20142170 A1 PE 20142170A1 PE 2014001473 A PE2014001473 A PE 2014001473A PE 2014001473 A PE2014001473 A PE 2014001473A PE 20142170 A1 PE20142170 A1 PE 20142170A1
Authority
PE
Peru
Prior art keywords
seq
sequence
group
amino acids
acids selected
Prior art date
Application number
PE2014001473A
Other languages
English (en)
Spanish (es)
Inventor
Dorothea KOMINOS
Jie Zhang
Alla Pritsker
Matthew Davison
Nicolas Baurin
Govindan Subramanian
Xin Chen
Han Li
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49261064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142170(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20142170A1 publication Critical patent/PE20142170A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Zoology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2014001473A 2012-03-28 2013-03-15 Anticuerpos frente a los ligandos del receptor b1 de bradicinina PE20142170A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261616845P 2012-03-28 2012-03-28
FR1350953 2013-02-04

Publications (1)

Publication Number Publication Date
PE20142170A1 true PE20142170A1 (es) 2015-01-07

Family

ID=49261064

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001473A PE20142170A1 (es) 2012-03-28 2013-03-15 Anticuerpos frente a los ligandos del receptor b1 de bradicinina

Country Status (38)

Country Link
US (5) US9376494B2 (enExample)
EP (2) EP2831113B1 (enExample)
JP (5) JP6779012B2 (enExample)
KR (4) KR102367723B1 (enExample)
CN (3) CN113773385B (enExample)
AR (1) AR090352A1 (enExample)
AU (2) AU2013240242B2 (enExample)
BR (1) BR112014024282A2 (enExample)
CA (1) CA2868353C (enExample)
CL (2) CL2014002590A1 (enExample)
CO (1) CO7111293A2 (enExample)
CR (1) CR20140440A (enExample)
CY (1) CY1121466T1 (enExample)
DK (2) DK2831113T3 (enExample)
DO (1) DOP2014000199A (enExample)
EA (1) EA201491784A1 (enExample)
ES (1) ES2673869T3 (enExample)
GT (1) GT201400192A (enExample)
HR (1) HRP20180928T1 (enExample)
HU (1) HUE037720T2 (enExample)
IL (1) IL234830B (enExample)
LT (1) LT2831113T (enExample)
MA (1) MA37407B1 (enExample)
MX (2) MX361874B (enExample)
MY (2) MY184037A (enExample)
NZ (1) NZ631543A (enExample)
PE (1) PE20142170A1 (enExample)
PH (1) PH12014501970A1 (enExample)
PL (1) PL2831113T3 (enExample)
PT (1) PT2831113T (enExample)
RS (1) RS57413B1 (enExample)
SG (2) SG11201405162YA (enExample)
SI (1) SI2831113T1 (enExample)
TR (1) TR201808486T4 (enExample)
TW (1) TWI605060B (enExample)
UA (1) UA117097C2 (enExample)
UY (1) UY34682A (enExample)
WO (1) WO2013148296A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102367723B1 (ko) * 2012-03-28 2022-02-28 사노피 브라디키닌 b1 수용체 리간드에 대한 항체
CU24446B1 (es) 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
CN105504049B (zh) * 2014-09-26 2019-07-05 艾托金生物医药（苏州）有限公司 宫颈癌相关的hpv e7蛋白单克隆抗体及其应用
KR102874711B1 (ko) 2015-12-15 2025-10-23 다케다 파머수티컬 컴패니 리미티드 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
AU2017259039B2 (en) 2016-05-02 2024-05-09 Prothena Biosciences Limited Antibodies recognizing tau
US10752679B2 (en) 2016-05-02 2020-08-25 Prothena Biosciences Limited Tau immunotherapy
EA201892417A1 (ru) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
CN110881274B (zh) * 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
WO2018208864A1 (en) * 2017-05-08 2018-11-15 Adimab, Llc Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
WO2019148186A1 (en) * 2018-01-29 2019-08-01 Silarus Therapeutics, Inc. Antibodies binding erfe and methods of use
JP7630834B2 (ja) 2019-03-03 2025-02-18 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
CN119306824B (zh) * 2024-10-08 2025-09-26 江苏埃尔迪生物科技有限公司 一种全价展示scFv的通用型M13噬菌体探针及其构建方法和应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0428534B1 (en) 1988-06-14 1995-03-29 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
EP0521985B1 (en) 1990-03-20 1997-09-24 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
EP0574395B1 (en) 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
AU3968897A (en) 1996-08-02 1998-02-25 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR20060067983A (ko) 1999-01-15 2006-06-20 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
EP3321282A1 (en) 2002-09-27 2018-05-16 Xencor, Inc. Optimized fc variants and methods for their generation
CA2502904C (en) 2002-10-15 2013-05-28 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP1706424B1 (en) 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
PL2471813T3 (pl) 2004-07-15 2015-09-30 Xencor Inc Zoptymalizowane warianty Fc
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
MX2007015781A (es) 2005-06-14 2008-02-15 Cytos Biotechnology Ag Conjugados antigenos y sus usos.
US8460362B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
AR063840A1 (es) * 2006-11-15 2009-02-25 Medarex Inc Anticuerpos humanos monoclonales para btla y metodos de uso
WO2008151204A1 (en) 2007-06-04 2008-12-11 Sequent Medical Inc. Methods and devices for treatment of vascular defects
TWI557136B (zh) * 2007-06-12 2016-11-11 Ａｃ免疫公司 特異性結合β-類澱粉蛋白之抗體及相關核酸分子、表現載體、細胞、組合物、套組、方法及用途
ES2672769T3 (es) 2007-08-29 2018-06-18 Sanofi Anticuerpos anti-CXCR5 humanizados, derivados de los mismos y sus usos
EA201692127A1 (ru) * 2007-11-07 2017-08-31 Селлдекс Терапьютикс Инк. Антитела, связывающиеся с человеческим dec-205
EP2420245A1 (en) * 2010-08-18 2012-02-22 Max-Delbrück-Centrum Für Molekulare Medizin Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
KR102367723B1 (ko) * 2012-03-28 2022-02-28 사노피 브라디키닌 b1 수용체 리간드에 대한 항체

Also Published As

Publication number Publication date
CN104334578A (zh) 2015-02-04
MA37407B1 (fr) 2018-03-30
AU2013240242B2 (en) 2018-02-08
CL2017003039A1 (es) 2018-03-16
TW201343671A (zh) 2013-11-01
US9879079B2 (en) 2018-01-30
EP3246339A1 (en) 2017-11-22
MX2018015914A (es) 2021-12-08
US9376494B2 (en) 2016-06-28
PH12014501970A1 (en) 2014-11-17
AU2013240242A1 (en) 2014-10-02
WO2013148296A1 (en) 2013-10-03
JP2021166538A (ja) 2021-10-21
JP6779012B2 (ja) 2020-11-04
MX361874B (es) 2018-12-18
KR20200121370A (ko) 2020-10-23
AU2018203081A1 (en) 2018-05-24
HK1206754A1 (en) 2016-01-15
CN113773385A (zh) 2021-12-10
NZ631543A (en) 2017-03-31
US20180222967A1 (en) 2018-08-09
KR20220031728A (ko) 2022-03-11
MY184037A (en) 2021-03-17
AR090352A1 (es) 2014-11-05
MA37407A1 (fr) 2016-05-31
SG11201405162YA (en) 2014-09-26
HUE037720T2 (hu) 2018-09-28
GT201400192A (es) 2015-07-29
US20150050270A1 (en) 2015-02-19
KR102035882B1 (ko) 2019-10-24
JP2024038036A (ja) 2024-03-19
EP2831113B1 (en) 2018-03-14
CA2868353C (en) 2023-10-31
ES2673869T3 (es) 2018-06-26
CN104334578B (zh) 2021-10-08
CY1121466T1 (el) 2020-05-29
BR112014024282A2 (pt) 2017-08-08
KR20150002679A (ko) 2015-01-07
SG10201702396QA (en) 2017-04-27
EP3246339B1 (en) 2019-10-09
CR20140440A (es) 2014-11-17
TWI605060B (zh) 2017-11-11
US20230399388A1 (en) 2023-12-14
JP2019050822A (ja) 2019-04-04
PT2831113T (pt) 2018-06-20
MX2014011688A (es) 2015-01-22
DK2831113T3 (en) 2018-06-25
EP2831113A1 (en) 2015-02-04
HRP20180928T1 (hr) 2018-07-27
TR201808486T4 (tr) 2018-07-23
US20160368976A1 (en) 2016-12-22
EA201491784A1 (ru) 2015-02-27
JP2025134874A (ja) 2025-09-17
KR20190121861A (ko) 2019-10-28
CN120441698A (zh) 2025-08-08
JP6912441B2 (ja) 2021-08-04
CN113773385B (zh) 2025-09-12
US20200115441A1 (en) 2020-04-16
DOP2014000199A (es) 2014-10-31
CL2014002590A1 (es) 2015-01-16
CO7111293A2 (es) 2014-11-10
KR102166083B1 (ko) 2020-10-16
SI2831113T1 (en) 2018-08-31
MY166157A (en) 2018-06-06
LT2831113T (lt) 2018-06-25
DK3246339T3 (da) 2020-01-27
IL234830B (en) 2018-11-29
KR102367723B1 (ko) 2022-02-28
JP7411609B2 (ja) 2024-01-11
PL2831113T3 (pl) 2018-08-31
US10465002B2 (en) 2019-11-05
UA117097C2 (uk) 2018-06-25
JP2015513903A (ja) 2015-05-18
CA2868353A1 (en) 2013-10-03
RS57413B1 (sr) 2018-09-28
UY34682A (es) 2013-10-31

Similar Documents

Publication Publication Date Title
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
CL2018001177A1 (es) Anticuerpos vinculados especificamente a pd-1 y sus usos.
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
PE20210115A1 (es) Anticuerpos anti-tau y uso de los mismos
PE20141017A1 (es) Anticuerpos del cea
PE20141151A1 (es) Proteinas de union al antigeno cd27l
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
CO6230999A2 (es) Anticuerpo anti-esclerostina
PE20180604A1 (es) Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana)
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
PE20150159A1 (es) Composiciones y metodos para anticuerpos que actuan sobre el factor p
NZ729158A (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
PE20170916A1 (es) Composiciones y metodos para anticuerpos dirigidos a bmp6
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
PE20181090A1 (es) Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38
NZ729913A (en) St2l antagonists and methods of use
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
NZ608660A (en) Anti-cd48 antibodies and uses thereof

Legal Events

Date Code Title Description
FG Grant, registration